摘要
三阳性乳腺癌(triple-positive breast cancer,TPBC)是乳腺癌分子分型中特殊的一类,以ER/PR/HER-2均阳性表达为特征,对化疗、靶向治疗、内分泌治疗都具有敏感性。虽然理论上联合治疗可能使患者获得更好的治疗效果,但是TPBC的治疗没有得到期望的预后。因此探索其临床特征、耐药机制及针对性治疗是今后的发展方向。
Triple-positive breast cancer is one of the special molecular subtype of breast cancer,characterized by the expression of ER,PR,HER-2,sensitive to chemotherapy,targeted therapy,endocrine therapy.Theoretically,combination therapy for its effect would be more effective,however,the treatment of TPBC did not achieve the desired prognosis.The future research should focus on the exploration of characteristics,resistance mechanism and targeted therapy.
作者
张国泰
符德元
Zhang Guotai;Fu Deyuan(Dalian Medical University,Liaoning Dalian 116044,China;Department of Thyroid and Breast Surgery,Northern Jiangsu People's Hospital,Jiangsu Yangzhou 225001,China.)
出处
《现代肿瘤医学》
CAS
2020年第4期687-690,共4页
Journal of Modern Oncology
关键词
三阳性
乳腺癌
治疗
triple-positive
breast cancer
therapy
